睿知中国医院研究地图
候选清单

广州中山大学

中山大学孙逸仙纪念医院

Sun Yat-sen Memorial Hospital

在本站收录的 53 种疾病中,这家医院列在其中 22 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

中山大学孙逸仙纪念医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma25 篇牵头论文牵头 5 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma10 篇牵头论文牵头 2 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma66 篇牵头论文牵头 10 项开放试验
  4. 胃癌Stomach cancer11 篇牵头论文牵头 5 项开放试验
  5. 肝母细胞瘤Hepatoblastoma2 篇牵头论文
  6. 骨肉瘤Osteosarcoma6 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma8 篇牵头论文牵头 1 项开放试验
  9. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma1 篇牵头论文
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia4 篇牵头论文
  12. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis4 篇牵头论文
  13. β 地中海贫血Beta thalassaemia6 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder0 篇牵头论文牵头 1 项开放试验
  15. IgG4相关性疾病IgG4-related disease4 篇牵头论文
  16. 肝包虫病Hepatic echinococcosis1 篇牵头论文
  17. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis3 篇牵头论文
  18. 白塞病Behçet disease1 篇牵头论文
  19. IgA 肾病IgA nephropathy7 篇牵头论文
  20. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  21. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  22. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文

未列出的收录疾病:视网膜母细胞瘤、脊索瘤、再生障碍性贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、特发性肺纤维化、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 1.1%。

牵头论文
25
2021–2025 年
牵头试验
14
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 6620222023: 5520232024: 6620242025: 442025

广州有 23 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2026-07
    登记号
    NCT07705243

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  2. 正在招募
    Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2026-07
    登记号
    NCT07706985

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  3. 正在招募
    Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
    分期
    III期
    开始
    2024-05
    登记号
    NCT06438627

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  4. 正在招募
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2024-06
    登记号
    NCT06455410

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院;另有 7 家列出的医院为研究中心佛山、南宁、广州、柳州、汕头、深圳

  5. 正在招募
    Deep Learning-based sbORN Diagnostic Model
    分期
    未注明
    开始
    2024-07
    登记号
    NCT06463392

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  6. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

  7. 正在招募
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2024-03
    登记号
    NCT06301165

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心东莞、佛山、广州、武汉、深圳

  8. 正在招募
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    分期
    未注明
    开始
    2024-04
    登记号
    NCT06308328

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院;另有 9 家列出的医院为研究中心上海、广州、成都、深圳、珠海、韶关

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与转移诱导/同步化疗副作用与生活质量
论文中的科室耳鼻喉/头颈外科神经内科肿瘤内科眼科/神经眼科
牵头的论文25
  1. The role of the CTBP2 mediated glycolytic pathway in nasopharyngeal carcinoma metastasis.2026Biochemical and biophysical research communications
  2. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.2026British journal of cancer免费全文
  3. Efficacy and safety of low-dose vs medium-dose bevacizumab for radiation-induced brain necrosis in nasopharyngeal carcinoma survivors.2026Neurological research
  4. Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.2025BMC medicine免费全文
  5. Development and Validation of a Nomogram Model for Predicting Non-keratinizing Nasopharyngeal Carcinoma by Combining Sex and Three EB Virus Antibodies.2025Cancer control : journal of the Moffitt Cancer Center免费全文
  6. Longitudinal observation of radiation-induced cognitive impairment and emotional dysfunction: Based on animal model and clinical cohort.2025Neuroscience
  7. The m6A reader YTHDF1 facilitates nasopharyngeal carcinoma proliferation and migration via c-MYC.2025The Journal of biological chemistry免费全文
  8. Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.2024Clinical and translational medicine免费全文
  9. IgG4-related disease with nasopharyngeal malignancy-like manifestations.2024Frontiers in immunology免费全文
  10. Targeting Cancer Mitochondria by Inducing an Abnormal Mitochondrial Unfolded Protein Response Leads to Tumor Suppression.2024International journal of medical sciences免费全文
  11. Age-specific characteristics of head and neck second primary malignancies in patients treated for nasopharyngeal carcinoma: a retrospective study.2024International journal of oral and maxillofacial surgery
  12. EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation.2024PLoS pathogens免费全文
  13. Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. A collision tumor of nasopharyngeal carcinoma and primary mantle cell lymphoma in the nasopharynx: a case report and review of the literature.2023BMC oral health免费全文
  15. Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor.2023Frontiers in immunology免费全文
  16. Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.2023Head & neck
  17. C2orf48 promotes the progression of nasopharyngeal carcinoma by regulating high mobility group AT-hook 2.2023Medical oncology (Northwood, London, England)
  18. A radiomics model for predicting the response to methylprednisolone in brain necrosis after radiotherapy for nasopharyngeal carcinoma.2023Radiation oncology (London, England)免费全文
  19. Progression and postoperative complications of osteoradionecrosis of the jaw: a 20-year retrospective study of 124 non-nasopharyngeal cancer cases and meta-analysis.2022BMC oral health免费全文
  20. Establishment and Validation of a Predictive Model for Radiation-Associated Aspiration Pneumonia in Patients with Radiation-Induced Dysphagia after Nasopharyngeal Carcinoma.2022Behavioural neurologyRCT免费全文
  21. Radiotherapy-Related Neurologic Complications in Patients with Nasopharyngeal Carcinoma: A Multicenter Epidemiologic Study in Southern China.2022Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  22. Nogo-B promotes invasion and metastasis of nasopharyngeal carcinoma via RhoA-SRF-MRTFA pathway.2022Cell death & disease免费全文
  23. Radiation optic neuropathy diagnosis in nasopharyngeal carcinoma patients with radiation encephalopathy.2022European journal of ophthalmology
  24. STRESS granule-associated RNA-binding protein CAPRIN1 drives cancer progression and regulates treatment response in nasopharyngeal carcinoma.2022Medical oncology (Northwood, London, England)免费全文
  25. En bloc resection and reconstruction in patients with advanced recurrent nasopharyngeal carcinoma and radiation-induced sarcoma of the head and neck.2021International journal of oral and maxillofacial surgery
中文论文(未计入)2
  1. [IgG4-related disease with nasopharyngeal malignancy-like manifestations].2022Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery免费全文
  2. [Transoral robotic nasopharyngectomy for local recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
  1. Deep Learning-based sbORN Diagnostic Model正在招募NCT06463392牵头方2024-07 启动
  2. Distribution of Bacteria in OME After Radiotherapy For NPC.状态不明NCT06523933牵头方2024-05 启动
  3. A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC状态不明NCT05949749牵头方2023-08 启动
  4. A Prospective, Randomized, Controlled Clinical Study of BET Combined With Tympanostomy Tube Insertion in the Treatment of Intractable OME After Radiotherapy for NPC状态不明NCT05449184牵头方不分期2022-06 启动
  5. Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis已暂停NCT02022293牵头方II期2017-01 启动
  6. Treatment of Bevacizumab Followed by Steroid in RN状态不明NCT04553510牵头方II期2016-01 启动
  7. Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma已完成NCT01621880牵头方II期2012-06 启动
  8. Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis已完成NCT01865201牵头方II期2009-03 启动
  9. Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma正在招募NCT07706985牵头方(推断)III期2026-07 启动
  10. Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma正在招募NCT07705243牵头方(推断)III期2026-07 启动
  11. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma正在招募NCT06455410牵头方(推断)II期2024-06 启动
  12. Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial正在招募NCT06438627牵头方(推断)III期2024-05 启动
  13. Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy已完成NCT03906058牵头方(推断)II期2019-04 启动
  14. Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma状态不明NCT03708822牵头方(推断)II期2018-10 启动
  15. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  16. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis正在招募NCT06308328研究中心2024-04 启动
  17. TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma正在招募NCT06301165研究中心II期2024-03 启动
  18. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  19. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
PubMed 以外找到的论文(未计入)38
  1. 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial2025Annals of Oncology论文
  2. 434 Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study2025Journal for ImmunoTherapy of Cancer会议摘要
  3. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncology论文
  4. A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physics论文
  5. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncology会议摘要
  6. AI-Enhanced Automated Planning System for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma: Development and Prospective Clinical Validation2025International Journal of Radiation Oncology*Biology*Physics论文
  7. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  8. Development and Performance Evaluation of an LLM-Based Automated Recommendation System for Radiotherapy Treatment Planning2025International Journal of Radiation Oncology*Biology*Physics论文
  9. Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial.2025Journal of Clinical Oncology会议摘要
  10. Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma2025Open Research (University of Surrey)论文
  11. Prior Knowledge-Guided Deep Learning Segmentation Algorithm for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physics论文
  12. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  13. WITHDRAWN: 1386P A deep learning-based time-habitat longitudinal MRI radiomics model for predicting short-term treatment outcomes in locally advanced nasopharyngeal carcinoma: A multi-center study2025Annals of Oncology撤稿
  14. 893P Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial2024Annals of Oncology论文
  15. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncology会议摘要
  16. Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II clinical trial2024Research Square预印本
  17. SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment2024bioRxiv (Cold Spring Harbor Laboratory)预印本
  18. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figshare数据集
  19. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023未列出期刊其他
  20. Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer2023未列出期刊其他
  21. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.2023Journal of Clinical Oncology会议摘要
  22. Enhanced radiosensitivity and chemoradiation efficacy in nasopharyngeal carcinoma via a dual-targeted SPION@polymer hybrid nanosensitizer2023NPG Asia Materials论文
  23. Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.2023Journal of Clinical Oncology会议摘要
  24. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  25. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  26. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figshare数据集
  27. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  28. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  29. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  30. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  31. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  32. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  33. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  34. Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage T any N3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.2022Journal of Clinical Oncology会议摘要
  35. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncology会议摘要
  36. Voxel-based radiomics outlines spatial heterogeneity of cerebral radiation necrosis (RN) associated with bevacizumab (Bev) response in head and neck radiotherapy (RT) patients.2022Journal of Clinical Oncology会议摘要
  37. Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.2021Journal of Clinical Oncology会议摘要
  38. Contouring Methods and Atlas of Organs at Risk2021Practical guides in radiation oncology书籍章节

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.3%。

牵头论文
10
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 3320232024: 3320242025: 222025

广州有 11 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-05
    登记号
    NCT07595770

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  2. 正在招募
    Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-03
    登记号
    NCT06339619

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能手术新辅助与综合治疗
论文中的科室普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. Right versus left thoracic approach esophagectomy for patients with neoadjuvant immunochemotherapy.2025Annals of medicine免费全文
  2. Single-Cell RNA-Seq Reveals the Effect of Commensal Bacteria on the Multistep Development of Esophageal Cancer.2025Cancer science免费全文
  3. Nomograms for predicting the prognosis in multiple primary esophageal squamous cell carcinoma.2024Annals of medicine免费全文
  4. Single-cell RNA sequencing reveals the MIF-ACKR3 receptor-ligand interaction between iCAFs and tumor cells in esophageal squamous cell carcinoma.2024Cellular signalling
  5. CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.2024Journal of experimental & clinical cancer research : CR免费全文
  6. A novel protein encoded by circUBE4B promotes progression of esophageal squamous cell carcinoma by augmenting MAPK/ERK signaling.2023Cell death & disease免费全文
  7. Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients.2023Frontiers in cellular and infection microbiology免费全文
  8. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.2023Journal of surgical oncology
  9. HN1L/AP-2γ/PLK1 signaling drives tumor progression and chemotherapy resistance in esophageal squamous cell carcinoma.2022Cell death & disease免费全文
  10. Organoid models combined with genome engineering and epigenome studies to define SOX2 function evolution in esophageal squamous cell carcinoma.2021Thoracic cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma正在招募NCT07595770牵头方II期2026-05 启动
  2. Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma正在招募NCT06339619牵头方II期2024-03 启动
PubMed 以外找到的论文(未计入)8
  1. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figshare数据集
  2. Artificial intelligence model for predicting the efficacy of sintilimab plus chemotherapy in treating patients with esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  3. Identification lymph node metastasis in esophageal squamous cell carcinoma using whole slide images and a hybrid network of multiple instance and transfer learning2023Biomedical Signal Processing and Control论文
  4. 359. INTRATUMORAL MICROBIOME IMPACTS IMMUNE INFILTRATES IN TUMOR MICROENVIRONMENT AND PREDICTS PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS2022Diseases of the Esophagus论文
  5. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  6. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figshare数据集
  7. Genomic profiling of Chinese esophageal squamous cell carcinoma patients and difference of genomic mutation between Chinese and American cohorts.2021Journal of Clinical Oncology会议摘要
  8. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 66 篇,占 0.4%。

牵头论文
66
2021–2025 年
牵头试验
18
任何状态,ClinicalTrials.gov
牵头的开放试验
10
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 8820222023: 121220232024: 191920242025: 18182025

广州有 14 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 13

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
    分期
    未注明
    开始
    2026-07
    登记号
    NCT07658833

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  2. 正在招募
    Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
    分期
    III期
    开始
    2025-10
    登记号
    NCT07267806

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  3. 正在招募
    Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
    分期
    II期
    开始
    2025-04
    登记号
    NCT07806292

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  4. 正在招募
    Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
    分期
    不分期
    开始
    2024-08
    登记号
    NCT06581315

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  5. 正在招募
    mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
    分期
    II期
    开始
    2024-02
    登记号
    NCT06607107

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  6. 正在招募
    Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
    分期
    II期
    开始
    2023-06
    登记号
    NCT05475613

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  7. 正在招募
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
    分期
    III期
    开始
    2023-07
    登记号
    NCT06172205

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  8. 即将招募
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07880106

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  9. 即将招募
    FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
    分期
    I/II期
    开始
    2025-01
    登记号
    NCT06409637

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  10. 即将招募
    Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
    分期
    不分期
    开始
    2025-01
    登记号
    NCT06749678

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  11. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  12. 即将招募
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    分期
    未注明
    开始
    2026-07
    登记号
    NCT07724951

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 6 家列出的医院为研究中心上海、南宁、哈尔滨、广州、青岛

  13. 即将招募
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    分期
    不分期
    开始
    2026-12
    登记号
    NCT07866612

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院;另有 8 家列出的医院为研究中心上海、北京、南京、广州、成都、福州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科病理/检验科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文66
  1. Targeting the Notch1-YY1-ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T-Cell-Driven Cancer Cell Pyroptosis.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. m6A-Modified circRAPGEF1 Interaction with IGF2BP3 Promotes Hepatocellular Carcinoma Progression via Reprogramming Aspartate Metabolism.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. TMEM88 modulates the proliferation and metastasis of HCC via the GSK-3β/β-catenin pathway.2025BMC cancer免费全文
  4. Multiparametric dual-energy computed tomography radiomics for predicting microvascular invasion in hepatocellular carcinoma.2025BMC medical imaging免费全文
  5. circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation.2025Cancer letters
  6. RPL35A Downregulation Suppresses Hepatocellular Carcinoma Cell Proliferation via NCAPG2 Inactivation.2025Cancer medicine免费全文
  7. LncRNA AFAP1-AS1 promoting residual tumor progression after insufficient radiofrequency ablation by up-regulating macropinocytosis in hepatocellular carcinoma.2025Cellular signalling
  8. Post-transarterial chemoembolization hypoxia-induced HIF-1α/WNT/β-catenin signaling promotes hepatocellular carcinoma progression via programed death ligand 1 upregulation.2025Clinical and experimental immunology
  9. Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  10. G6PC1 expression as a prognostic biomarker associated with metabolic reprogramming and tumor microenvironment in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  11. Unveiling B7/CD28 family proteins in hepatocellular carcinoma: insights into communication and prognostic significance.2025Frontiers in immunology免费全文
  12. Ribonuclease P/MRP subunit RPP40 coordinates the transcription of pre-rRNA and ribosomal protein genes to promote Hepatocellular carcinoma malignancy.2025Gene
  13. Co-Delivery of Chemotherapy and Anti-Angiogenic Lipid via DPPA-LNPs Potentiates Anti-PD-1 Immunotherapy.2025International journal of nanomedicine免费全文
  14. A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study.2025International journal of surgery (London, England)免费全文
  15. Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis.2025Molecular cancer免费全文
  16. Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma.2025Oncology research免费全文
  17. Analysis of the optimal patterns of serum alpha fetoprotein (AFP), AFP-L3% and protein induced by vitamin K absence or antagonist-II (PIVKA-II) detection in the diagnosis of liver cancers.2025PeerJ免费全文
  18. Safety and efficacy of laparoscopic portal territory fluorescence navigation-guided anatomical liver resection in hepatocellular carcinoma patients.2025Surgical endoscopy
  19. MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma.2025Toxicological sciences : an official journal of the Society of Toxicology免费全文
  20. A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells.2024Advanced healthcare materials
  21. The Taping Game for the Complex G8 Glissonean Approach Is the Most Effective Technique for Laparoscopic Anatomic S8 Resection of Dandelion-Patterned Hepatic Pedicles.2024Annals of surgical oncology
  22. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.2024Apoptosis : an international journal on programmed cell death
  23. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma.2024British journal of hospital medicine (London, England : 2005)
  24. Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.2024Cancer immunology, immunotherapy : CII免费全文
  25. SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression.2024Cancer science免费全文
  26. CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.2024Cell death & disease免费全文
  27. A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  28. Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  29. Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies.2024Clinical and experimental medicine免费全文
  30. Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  31. Identification of immunosenescence of unconventional T cells in hepatocellular carcinoma.2024Computational biology and chemistry
  32. Applying image features of proximal paracancerous tissues in predicting prognosis of patients with hepatocellular carcinoma.2024Computers in biology and medicine
  33. Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent.2024Current pharmaceutical design
  34. Causal Effect of Immunocytes, Plasma Metabolites, and Hepatocellular Carcinoma: A Bidirectional Two-Sample Mendelian Randomization Study and Mediation Analysis in East Asian Populations.2024Genes免费全文
  35. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.2024Journal for immunotherapy of cancer免费全文
  36. Hepatitis B Virus X Protein Represses Expression of Tumor Suppressor PTPN18 in Hepatocellular Carcinoma.2024Molecular cancer research : MCR
  37. Atractylenolide II regulates the proliferation, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway.2024Naunyn-Schmiedeberg's archives of pharmacology
  38. Downstaging of Hepatocellular Carcinoma Before Liver Transplantation: Current Advances in Selection Criteria and Therapeutic Options.2024Transplantation proceedings
  39. Exploring the efficacy of 18F-FDG PET/CT in hepatocellular carcinoma diagnosis: role of Ki-67 index and tumor differentiation.2023Abdominal radiology (New York)免费全文
  40. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.2023Acta biomaterialia
  41. Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  42. Development and validation of web-based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database.2023Cancer medicine免费全文
  43. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma based on B-Mode US and CEUS.2023European radiology
  44. HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  45. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.2023Journal of advanced research免费全文
  46. Integrative analysis of lactylation-related genes and establishment of a novel prognostic signature for hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  47. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.2023Journal of gastroenterology and hepatology
  48. Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma.2023Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  49. Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation.2023Nature communications免费全文
  50. Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.2023The Journal of clinical investigation免费全文
  51. Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  52. CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway.2022Cell death & disease免费全文
  53. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.2022Digestive diseases and sciences
  54. p62 Promotes Malignancy of Hepatocellular Carcinoma by Regulating the Secretion of Exosomes and the Localization of β-Catenin.2022Frontiers in bioscience (Landmark edition)
  55. A functional loop between YTH domain family protein YTHDF3 mediated m6A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma.2022Journal of experimental & clinical cancer research : CR免费全文
  56. INPP5F translocates into cytoplasm and interacts with ASPH to promote tumor growth in hepatocellular carcinoma.2022Journal of experimental & clinical cancer research : CR免费全文
  57. Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.2022Oncogene
  58. Utility of Sonazoid-Enhanced Ultrasound for the Macroscopic Classification of Hepatocellular Carcinoma: A Meta-analysis.2022Ultrasound in medicine & biology
  59. Genome-wide identification of microRNA targets reveals positive regulation of the Hippo pathway by miR-122 during liver development.2021Cell death & disease免费全文
  60. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.2021Cell death & disease免费全文
  61. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data.2021Hepatology international
  62. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.2021Oncogene免费全文
  63. miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A.2021Oxidative medicine and cellular longevity免费全文
  64. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.2021RNA biology免费全文
  65. Global analysis of gene expression signature and diagnostic/prognostic biomarker identification of hepatocellular carcinoma.2021Science progress免费全文
  66. Totally laparoscopic anatomic S7 segmentectomy using in situ split along the right intersectoral and intersegmental planes.2021Surgical endoscopy
中文论文(未计入)1
  1. [Structuring process approach to laparoscopic anatomical liver central lobectomy for hepatocellular carcinoma].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
它在 ClinicalTrials.gov 上的全部试验(任何状态)30
  1. Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer即将招募NCT07880106牵头方2026-10 启动
  2. TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC正在招募NCT07658833牵头方2026-07 启动
  3. Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma即将招募NCT06749678牵头方不分期2025-01 启动
  4. Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study正在招募NCT07806292牵头方II期2025-04 启动
  5. FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation即将招募NCT06409637牵头方I/II期2025-01 启动
  6. Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma正在招募NCT06581315牵头方不分期2024-08 启动
  7. mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria正在招募NCT06607107牵头方II期2024-02 启动
  8. Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC正在招募NCT06172205牵头方III期2023-07 启动
  9. Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation正在招募NCT05475613牵头方II期2023-06 启动
  10. Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy Strategy状态不明NCT06594289牵头方不分期2024-09 启动
  11. Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection状态不明NCT05913583牵头方2023-04 启动
  12. Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma状态不明NCT05924997牵头方I/II期2023-07 启动
  13. mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC状态不明NCT05412589牵头方II期2022-06 启动
  14. Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC已完成NCT06818097牵头方2021-10 启动
  15. Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery已完成NCT04962958牵头方II期2021-12 启动
  16. TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer状态不明NCT05550025牵头方II期2021-12 启动
  17. Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection状态不明NCT02131441牵头方不分期2013-07 启动
  18. Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC正在招募NCT07267806牵头方(推断)III期2025-10 启动
  19. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma即将招募NCT07866612研究中心不分期2026-12 启动
  20. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study即将招募NCT07724951研究中心2026-07 启动
  21. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  22. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification状态不明NCT05313282研究中心III期2022-06 启动
  23. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)状态不明NCT05214339研究中心II期2022-03 启动
  24. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  25. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  26. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  27. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  28. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  29. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  30. Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma状态不明NCT02616926研究中心不分期2015-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.1%。

牵头论文
11
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 1120232024: 3320242025: 112025

广州有 16 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Large Language Models Assist in Tumor MDT
    分期
    不分期
    开始
    2026-01
    登记号
    NCT07504367

    年龄 25 岁 至 33 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  2. 正在招募
    Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
    分期
    不分期
    开始
    2024-06
    登记号
    NCT05892289

    年龄 20 岁 至 80 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  3. 即将招募
    Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
    分期
    II期
    开始
    2026-06
    登记号
    NCT06365008

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  4. 即将招募
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07880106

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  5. 即将招募
    Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05890339

    年龄 20 岁 至 80 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  6. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能手术腹膜转移与晚期
论文中的科室肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文11
  1. Clinicopathological characterization of gastric amphicrine carcinoma: A case series.2026Annals of diagnostic pathology
  2. Discovery of highly potent marine-derived compound Penicolinate H reveals SREBP-1 mediated lipogenesis as a druggable vulnerability in gastric cancer.2025Journal of translational medicine免费全文
  3. Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer.2024Aging免费全文
  4. A β-Galactosidase-Activated Fluorogenic Reporter for the Detection of Gastric Cancer In Vivo and in Urine.2024Analytical chemistry
  5. Artificial intelligence model for perigastric blood vessel recognition during laparoscopic radical gastrectomy with D2 lymphadenectomy in locally advanced gastric cancer.2024BJS open免费全文
  6. Marine fungus-derived alkaloid inhibits the growth and metastasis of gastric cancer via targeting mTORC1 signaling pathway.2023Chemico-biological interactions
  7. Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer.2022Cancer science免费全文
  8. Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer.2022Cell death & disease免费全文
  9. Immune-Related LncRNAs to Construct a Prognosis Risk-Assessment Model for Gastric Cancer.2022Current oncology (Toronto, Ont.)免费全文
  10. Nomogram for predicting mandatory ICU admission after gastrectomy for gastric cancer.2021Annals of palliative medicine
  11. Development and validation of a nomogram to predict intraoperative blood transfusion for gastric cancer surgery.2021Transfusion medicine (Oxford, England)RCT
中文论文(未计入)1
  1. [Laparoscopy and endoscopy cooperative surgery in the treatment of stomach neoplasms].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Large Language Models Assist in Tumor MDT正在招募NCT07504367牵头方不分期2026-01 启动
  2. Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer即将招募NCT07880106牵头方2026-10 启动
  3. Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer即将招募NCT06365008牵头方II期2026-06 启动
  4. Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer正在招募NCT05892289牵头方不分期2024-06 启动
  5. Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer即将招募NCT05890339牵头方不分期2023-06 启动
  6. Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study已完成NCT06897306牵头方2024-10 启动
  7. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  8. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors进行中,不再招募NCT06257264研究中心I期2024-03 启动
  9. Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing状态不明NCT06036563研究中心2023-09 启动
  10. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  11. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  12. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  13. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

广州有 8 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 3320242025: 002025

广州有 33 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文6
  1. HP1 enhances radio- and chemotherapy resistance in osteosarcoma via PARP1-dependent transcriptional repression and HR repair.2026Cancer letters
  2. SETD8 inhibits apoptosis and ferroptosis of Ewing's sarcoma through YBX1/RAC3 axis.2024Cell death & disease
  3. AURKA inhibition induces Ewing's sarcoma apoptosis and ferroptosis through NPM1/YAP1 axis.2024Cell death & disease
  4. DNA Damage-Sensitized metal phenolic nanosynergists potentiate Low-Power phototherapy for osteosarcoma therapy.2024Journal of colloid and interface science
  5. ERRα contributes to HDAC6-induced chemoresistance of osteosarcoma cells.2023Cell biology and toxicology
  6. IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells.2022Journal of translational medicine
早期论文(2016–2020 年)5
  1. Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma.2020Molecular cancer research : MCR
  2. Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma.2020Signal transduction and targeted therapy
  3. Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.2019Journal of cellular and molecular medicine
  4. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.2019Nucleic acids research
  5. Estrogen-related receptor α participates transforming growth factor-β (TGF-β) induced epithelial-mesenchymal transition of osteosarcoma cells.2017Cell adhesion & migration

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 13 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.7%。

牵头论文
8
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 4420232024: 2220242025: 002025

广州有 23 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
    分期
    II期
    开始
    2025-05
    登记号
    NCT06933394

    年龄 18 个月 至 18 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科儿科神经内科
牵头的论文8
  1. Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.2024BMC cancer
  2. Arsenic trioxide induces ferroptosis in neuroblastoma by mediating GPX4 transcriptional inhibition.2024Clinical and translational science
  3. Arsenic Trioxide inhibits Activation of Hedgehog Pathway in Human Neuroblastoma Cell Line SK-N-BE(2) Independent of Itraconazole.2023Anti-cancer agents in medicinal chemistry
  4. Serum brain-derived neurotrophic factor (BDNF) as predictors of childhood neuroblastoma relapse.2023BMC cancer
  5. Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals.2023BMC pediatrics
  6. α-Synuclein Induces Neuroinflammation Injury through the IL6ST-AS/STAT3/HIF-1α Axis.2023International journal of molecular sciences
  7. Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  8. Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.2021Oncology research
中文论文(未计入)2
  1. [A multicenter study of allogeneic hematopoietic stem cell transplantation for stage 4/M neuroblastoma].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Short-term results of a multicenter study based on a modified N7 induction regimen combined with arsenic trioxide in the treatment of children with high-risk neuroblastoma].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
早期论文(2016–2020 年)6
  1. Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. α-synuclein accumulation in SH-SY5Y cell impairs autophagy in microglia by exosomes overloading miR-19a-3p.2019Epigenomics
  3. Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells.2018Biological research
  4. Analysis of treatment of large abdominal malignancies in children complicated with abdominal compartment syndrome: Report of six cases.2017Medicine
  5. Rifampicin inhibits rotenone-induced microglial inflammation via enhancement of autophagy.2017Neurotoxicology
  6. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.2016International journal of oncology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma正在招募NCT06933394牵头方II期2025-05 启动
  2. Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma即将招募NCT05303727牵头方II期2022-08 启动
  3. Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma进行中,不再招募NCT03503864牵头方(推断)II期2017-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

广州有 9 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.06%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 14 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-06
    登记号
    NCT06574568

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州

  2. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植联合用药
牵头的论文1
  1. The efficacy and safety of lenalidomide in the treatment of multiple myeloma patients after allo-hematopoietic stem-cell transplantation: a systematic review and meta-analysis.2021Annals of palliative medicine
中文论文(未计入)1
  1. [Plasmablastic plasma cell myeloma: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06574568研究中心I期2024-06 启动
  3. Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma状态不明NCT05422027研究中心I/II期2022-07 启动
  4. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 4420242025: 002025

广州有 8 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06580301

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、广州、徐州、杭州、贵阳、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学儿童微小残留病与复发
论文中的科室肿瘤内科儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.0%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025

广州有 5 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童诊断与预后治疗方案
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.9%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 442025

广州有 23 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
    分期
    I期
    开始
    2024-01
    登记号
    NCT06465550

    年龄 3 岁 至 35 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、南宁、广州

  2. 正在招募
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    分期
    II期
    开始
    2019-11
    登记号
    NCT04143724

    年龄 6 岁 至 17 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心南宁、广州、成都、深圳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科
牵头的论文6
  1. Clinical patterns of thalidomide in the treatment of transfusion-dependent β-thalassaemia in children: a prospective single-arm study in China.2025Annals of medicine
  2. A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.2025Hematology (Amsterdam, Netherlands)
  3. Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.2025Hemoglobin
  4. Creating New Cis-Regulatory Elements of HBD to Reactivate Delta-Globin.2025Human gene therapy
  5. A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia.2024Stem cell research & therapy
  6. Indicators of glucose dysregulation and the relationship with iron overload in Chinese children with beta thalassemia major.2022Pediatric diabetes
中文论文(未计入)2
  1. [Prevalence Rate and Risk Factors of Hypothyroidism in Children with Beta Thalassemia Major in Zhuhai Area].2021Zhongguo shi yan xue ye xue za zhi
  2. [Research Progress on Gene Therapy for β-thalassemia---Review].2021Zhongguo shi yan xue ye xue za zhi
早期论文(2016–2020 年)5
  1. Severe hypertension is an independent risk factor for posterior reversible encephalopathy syndrome post-hematopoietic cell transplantation in children with thalassemia major.2019Clinical transplantation
  2. Modified conditioning regimen improves outcomes of unrelated donor peripheral blood stem cell transplantation for β-thalassaemia major patients.2018Pediatric blood & cancer
  3. Hematopoietic stem cell transplantation for children with β-thalassemia major: multicenter experience in China.2018World journal of pediatrics : WJP
  4. [Clinical analysis of three cases with beta-thalassemia].2018Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. [Analysis of the influence of iron overload in glucose metabolism in thalassemia major patients].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors状态不明NCT06026839牵头方2023-10 启动
  2. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major正在招募NCT06465550研究中心I期2024-01 启动
  3. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia正在招募NCT04143724研究中心II期2019-11 启动
  4. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia进行中,不再招募NCT05577312研究中心I/II期2022-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年没有牵头视神经脊髓炎谱系疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

广州有 9 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
    分期
    未注明
    开始
    2024-01
    登记号
    NCT06541626

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院广州

  2. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.6%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 1120242025: 002025

广州有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题诊断与鉴别胰腺与胆管肺与胸部
论文中的科室消化/肝病科耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 2 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025

广州有 13 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

广州有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科
牵头的论文1
  1. Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.2023Frontiers in immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.9%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 1120232024: 1120242025: 112025

广州有 20 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    分期
    未注明
    开始
    2020-05
    登记号
    NCT05190848

    年龄 16 岁 至 65 岁(登记的条件)

    牵头:广东省人民医院;另有 4 家列出的医院为研究中心广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头

广州有 9 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
    分期
    III期
    开始
    2025-12
    登记号
    NCT07296458

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 1 家列出的医院为研究中心广州、西安

  2. 正在招募
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    分期
    II/III期
    开始
    2023-02
    登记号
    NCT05749822

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心Yan’an、北京、南京、天津、广州、成都、昆明、沈阳、西安、郑州、长沙

  3. 正在招募
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    分期
    III期
    开始
    2023-02
    登记号
    NCT05751967

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 6 家列出的医院为研究中心兰州、南京、天津、广州、成都、沈阳、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 8 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

中山大学孙逸仙纪念医院

Sun Yat-sen Memorial Hospital

广州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Sun Yat-Sen Memorial Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital and Sun Yat-sen Memorial Hospital; Sun Yat-sen Memorial Hospital Affiliated to Sun Yat-sen University; Sun Yat-sen Memorial Hospitall; Sun Yatsen Memorial Hospital of Sun Yat-sen University; Second Affiliated Hospital of Sun Yat-sen

提出更正下载数据